Clinical impact of antibody formation to botulinum toxin A in children.
We studied the clinical impact of neutralizing antibodies to botulinum toxin A that occurred during long-term treatment of children between 1993 and 2001. Antibodies were found in high titers in 35 of 110 (31.8%) samples from individual patients. Antibody formation correlated with secondary nonresponse (p < 0.001). The most significant risk factors for antibody formation were the frequency of treatments (p = 0.0001) and the injection of a higher weight-adapted maximum dose per treatment (p = 0.001).
Herrmann
Jochen
J
Department of Pediatric Radiology, University Clinic Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Geth
Katrin
K
Mall
Volker
V
Bigalke
Hans
H
Schulte Mönting
Jürgen
J
Linder
Michaela
M
Kirschner
Jan
J
Berweck
Steffen
S
Korinthenberg
Rudolf
R
Heinen
Florian
F
Fietzek
Urban M
UM
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood; D019274:Botulinum Toxins, Type A / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male
D000907:Antibodies, Bacterial; D019274:Botulinum Toxins, Type A